Innovate to care

Your partner in lateral flow test development
View case study
Latest News

Our expertise

Latest news

By Dr Kevin Land

GHLabs x GADx: PoC innovation in molecular diagnostics

The sensitivity of molecular testing is now being revolutionised for point-of-care (PoC) usage. PCR, known for its high sensitivity and specificity, is the gold standard in diagnosing many infectious…
New CEO at GADx, Dr Mark Street-Docherty
By GADx Team

New CEO at GADx, Dr Mark Street-Docherty

It is with great pleasure that Mologic Ltd t/a Global Access Diagnostics (GADx), announces the appointment of our new CEO, starting 1st February 2024, Dr Mark Street-Docherty.  Mark brings…
Packets of the IT-Leish rapid diagnostic test (RDT) for visceral leishmaniasis are displayed against a gradient background transitioning from teal to purple. Each white packet is clearly labeled with identification details including "IT LEISH", lot numbers, and expiration dates, along with the IVD (in vitro diagnostic) symbol, emphasizing their use in medical diagnostics. The packets are partially overlapped, focusing on their essential information and sterile packaging.
By Dr Sophie Owen

GADx reintroduces IT LEISH, the rapid diagnostic test for visceral leishmaniasis

Global Access Diagnostics (GADx), a social enterprise prioritising equitable access to diagnostics, today announced the launch of IT LEISH, a rapid diagnostic test (RDT) for visceral leishmaniasis (VL). The…
More news

Frequent testing is invaluable and so it is vital to find ways to drive down the cost of kits and increase production levels. As a social enterprise, GADx can transform this process because it ‘breaks the link’ of ‘having to make profit for shareholders’.

Paul Davis
Co-founder of Mologic and pioneer of lateral flow diagnostics.